Effects of a CYP2E1 inhibitory mAb, DASO2, or PMSF on covalent binding of [14C-carbonyl]-VC to lung microsomal proteins
| Exp. | pmol [14C-carbonyl]-VC/mg protein3-a | Exp. | pmol [14C-carbonyl]-VC/mg protein3-a |
|---|---|---|---|
| − mAb + VC − NADPH | 1.90 ± 0.07 | − DASO2 + VC − NADPH | 2.81 ± 0.23 |
| − mAb + VC + NADPH | 5.50 ± 0.313-b | − DASO2 + VC + NADPH | 7.22 ± 1.023-c |
| + mAb + VC + NADPH | 2.93 ± 0.28 | + DASO2 + VC + NADPH | 3.47 ± 0.76 |
| + HyHel 9 + VC + NADPH | 5.74 ± 0.273-b | + PMSF + VC + NADPH | 9.74 ± 0.53c,d |
↵3-a Data are expressed as mean ± S.D. of quadruplicate determinations from three or four different microsomal preparations and were analyzed by one-way ANOVA and the Student–Newman–Keuls test; p < .05.
↵3-b Significantly different from (− mAb + VC − NADPH) and (+ mAb + VC + NADPH).
↵3-c Significantly different from (− DASO2 + VC − NADPH) and (+ DASO2 + VC + NADPH).
3-d Significantly different from (− DASO2 + VC + NADPH).